1.Focusing on the treatment of chronic hepatitis B.
Chinese Journal of Hepatology 2009;17(10):721-721
2.Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients.
Tatsuo KANDA ; Osamu YOKOSUKA ; Masao OMATA
Chinese Medical Journal 2013;126(23):4568-4574
OBJECTIVETo review the updated research on direct antiviral agents (DAAs)-including regimens for hepatitis C virus (HCV), and focus on "difficult-to-treat" HCV-infected patients.
DATA SOURCESThe literature concerning DAAs and hepatitis C cited in this review was collected from PubMed and Google Scholar databases published in English up to July 2013.
STUDY SELECTIONData from published articles regarding HCV and DAAs in clinical trials and in clinical use were identified and reviewed.
RESULTSIt was recognized that some "difficult-to-treat" patients would still exist, even though stronger treatments using such as DAAs, including telaprevir and boceprevir, which lead to higher sustained virological response rates, are available. Such patients include those with advanced fibrosis/cirrhosis, elderly persons, children, HCV-human immunodeficiency virus co-infected patients, HCV-infected recipients, and so on.
CONCLUSIONSCertain "difficult-to-treat" patients would still exist, even though stronger treatment is available. Although evidence from clinical trials is still lacking, interferon-sparing regimens could have stronger effects for eradicating HCV in such cases.
Antiviral Agents ; pharmacology ; therapeutic use ; Hepacivirus ; drug effects ; pathogenicity ; Hepatitis C, Chronic ; drug therapy ; Humans
4.Traditional Uses, Phytochemistry, Pharmacology and Toxicology of Rhizoma phragmitis: A Narrative Review.
Yuan REN ; Ge-Dan CUI ; Li-Sha HE ; Huan YAO ; Chang-Yan ZI ; Yong-Xiang GAO
Chinese journal of integrative medicine 2022;28(12):1127-1136
Rhizoma phragmitis is a common Chinese herbal medicine whose effects are defined as 'clearing heat and fire, promoting fluid production to quench thirst, eliminating irritability, stopping vomiting, and disinhibiting urine'. During the Novel Coronavirus epidemic in 2020, the Weijing Decoction and Wuye Lugen Decoction, with Rhizoma phragmitis as the main herbal component, were included in The Pneumonia Treatment Protocol for Novel Coronavirus Infection (Trial Version 5) due to remarkable antiviral effects. Modern pharmacological studies have shown that Rhizoma phragmitis has antiviral, antioxidative, anti-inflammatory, analgesic, and hypoglycemic functions, lowers blood lipids and protects the liver and kidney. This review aims to provide a systematic summary of the botany, traditional applications, phytochemistry, pharmacology and toxicology of Rhizoma phragmitis.
Humans
;
Plant Extracts/pharmacology*
;
Rhizome
;
Drugs, Chinese Herbal/therapeutic use*
;
Antioxidants/therapeutic use*
;
Antiviral Agents/therapeutic use*
;
Medicine, Chinese Traditional
;
Phytochemicals/therapeutic use*
;
Ethnopharmacology
;
COVID-19 Drug Treatment
5.Progress of research on Inonotus obliquus.
Xiu-hong ZHONG ; Kuang REN ; Shi-jie LU ; Shu-yan YANG ; Dong-zhi SUN
Chinese journal of integrative medicine 2009;15(2):156-160
Inonotus obliquus has high nutritional and medicinal value, especially in treating malignant tumors, diabetes, cardiovascular disease and AIDS, attracting significant attention from scholars in recent years. In this paper, the biological characteristics, chemical composition and pharmacologic effects of Inonotus obliquus were summarized. And the applications in medicine and food were introduced. Future research on Inonotus obliquus was also discussed in order to make Inonotus obliquus obtain effective exploitation and satisfy people's demands.
Anti-Inflammatory Agents
;
chemistry
;
pharmacology
;
therapeutic use
;
Antineoplastic Agents
;
chemistry
;
pharmacology
;
therapeutic use
;
Antioxidants
;
chemistry
;
pharmacology
;
therapeutic use
;
Antiviral Agents
;
chemistry
;
pharmacology
;
therapeutic use
;
Basidiomycota
;
chemistry
;
Biomedical Research
;
trends
;
Drugs, Chinese Herbal
;
chemistry
;
pharmacology
;
therapeutic use
;
Humans
;
Hypoglycemic Agents
;
chemistry
;
pharmacology
;
therapeutic use
;
Platelet Aggregation Inhibitors
;
chemistry
;
pharmacology
;
therapeutic use
;
Triterpenes
;
chemistry
;
isolation & purification
6.Pharmacologic treatment of SARS: current knowledge and recommendations.
Annals of the Academy of Medicine, Singapore 2007;36(6):438-443
The severe acute respiratory syndrome (SARS) pandemic caught the world by surprise in 2003 and spread rapidly within a relatively short period of time. Hence, randomised placebo-controlled clinical trials on the treatment of SARS were not possible. Our understanding was obtained from observational, cohort studies, case series and reports. Nevertheless, such information is useful in providing clinical management guidelines and directing future research in case SARS recurs. Early in the pandemic, a combination of ribavirin and corticosteroids was adopted as the standard treatment in Hong Kong, Canada and elsewhere because of the apparent good results of the first few patients. Subsequent reports showed that ribavirin was associated with a high rate of toxicity and lacked in vitro antiviral effect on SARS-coronavirus (SAR-CoV). The timing and dosage regimens of steroid in the treatment of SARS are controversial. Pulse methylprednisolone 250 to 500 mg/day for 3 to 6 days has been reported to have some efficacy in a subset of patients with "critical SARS", i.e., critically ill SARS patients with deteriorating radiographic consolidation, increasing oxygen requirement with PaO2 <10 kPa or SpO2 <90% on air, and respiratory distress (rate of 30/min). Prolonged therapy with high-dose steroids, in the absence of an effective antimicrobial agent, could predispose patients to complications such as disseminated fungal infection, and avascular necrosis. Kaletra (400 mg ritonavir and 100 mg lopinavir), a protease inhibitor used in the treatment of human immunodeficiency virus infection, may be considered for early treatment of SARS patients, preferably in a randomised double-blind placebo-controlled clinical trial setting. Interferon (IFN) is not recommended as standard therapy in SARS. However, there are enough data on in vitro activity of IFN preparations and a few clinical studies for these products to support a controlled trial if SARS recurs. Many other experimental treatments have been tried in an uncontrolled manner, and they should not be recommended as standard therapy.
Adrenal Cortex Hormones
;
pharmacology
;
therapeutic use
;
Antiviral Agents
;
pharmacology
;
therapeutic use
;
Clinical Competence
;
Disease Outbreaks
;
prevention & control
;
Global Health
;
Humans
;
Immunoglobulins
;
pharmacology
;
therapeutic use
;
Immunologic Factors
;
pharmacology
;
therapeutic use
;
Interferons
;
pharmacology
;
therapeutic use
;
Lopinavir
;
Practice Guidelines as Topic
;
Protease Inhibitors
;
pharmacology
;
therapeutic use
;
Pyrimidinones
;
pharmacology
;
therapeutic use
;
Ribavirin
;
pharmacology
;
therapeutic use
;
SARS Virus
;
drug effects
;
Severe Acute Respiratory Syndrome
;
drug therapy
;
epidemiology
7.Research progress of neuraminidase inhibitors for anti-influenza.
Ai-Lin LIU ; Hai-Di WANG ; Fan YANG ; Guan-Hua DU
Acta Pharmaceutica Sinica 2009;44(9):935-942
Influenza is a global contagious disease, which causes hundreds of thousands of people deaths. And new subtype of influenza may cause pandemic influenza, and lead to more serious consequence. Drugs for anti-influenza have played very important roles in influenza treatment and prevention, especially neuraminidase inhibitors are effective on both influenza A and B which have more safety and tolerance, therefore they have been widely used for influenza treatment. However, several viral drug-resistant cases have been reported. In this paper, the clinic therapy, prevention and drug resistance of neuraminidase inhibitors, including zanamivir, oseltamivir and peramivir, and progress in the research and development in our country are presented in order to promote research and development of new drugs for influenza treatment and prevention.
Antiviral Agents
;
pharmacology
;
therapeutic use
;
Drug Resistance, Viral
;
drug effects
;
Enzyme Inhibitors
;
pharmacology
;
therapeutic use
;
Humans
;
Influenza, Human
;
drug therapy
;
prevention & control
;
virology
;
Neuraminidase
;
antagonists & inhibitors
;
Oseltamivir
;
pharmacology
;
therapeutic use
;
Zanamivir
;
pharmacology
;
therapeutic use
8.Lamivudine-resistant analysis and management for chronic hepatitis B patients with initial lamivudine therapy.
Hui XU ; Yang CHEN ; Ling-Li HE ; Bing-Jun LEI ; Xue-Zhong LEI
Chinese Journal of Hepatology 2011;19(6):427-430
OBJECTIVETo study the factors influencing the long-term usage of lamivudine (LAM) in chronic hepatitis B (CHB) patients and the management after drug-resistance.
METHODS383 cases of naive CHB patients in our outpatient clinic were treated with lamivudine (100 mg/d) and followed up for at least over 1 year from 2001 to 2010. 129 cases encountered lamivudine-resistance and were then divided into two groups: patients in group A were switched to adefovir dipivoxil (ADV) alternative treatment and those patients in group B were added with ADV for continuous treatment. Efficacy assessment factors included serum HBV markers, HBV DNA, ALT, AFP and other biochemical indicators.
RESULTSAmong the 383 cases, patients with HBV DNA negative conversion (PCR below test line) at 3 months, 6 months, 1 year, 2 years, 3 years and > 3 years after initial treatment were respectively 156 cases (40.7%), 213 cases (55.6%), 228 cases (59.5% ), 217cases (56.7%), 214 cases (55.9%) and 213 cases (55.6%). HBeAg/HBeAb seroconversion occurred in 62 cases (22.6%). 12 cases were found with primary LAM resistance, 129 cases with HBV breakthrough and rebound, the cumulative resistance rate was 36.8% and the cumulative rebound rate was 34.8%. High baseline viral load, baseline ALT levels < 2 ULN, Lower virologic response rate at week 24 were associated with a higher rebound rate (chi2 is 35.716, 8.728, 43.534, respectively, all with P < 0.01).Viral breakthrough and rebound occurred in 112 patients (86.8%) within 1 year and a half, 123 patients (95.3%) occurred at the end of 2 years and no patient with viral breakthrough and rebound after 5 years. For the patients with viral rebound in group A and group B, the rates of HBV DNA loss were 22.7% (15/66) and 58.7% (37/63) respectively, and the viral response rates were 59.1% (39/66) and 87.3% (52/63) respectively, with chi2 values equaled 17.364 and 12.975 respectively (P < 0.01).
CONCLUSIONFor the chronic hepatitis B patients on initial treatment with lamivudine, the viral rebound occurred mainly within 2 years. LAM combined with ADV is more effective than ADV alone for lamivudine-resistant patients.
Adenine ; analogs & derivatives ; pharmacology ; therapeutic use ; Adolescent ; Adult ; Aged ; Antiviral Agents ; pharmacology ; therapeutic use ; Drug Resistance, Viral ; Female ; Follow-Up Studies ; Hepatitis B, Chronic ; drug therapy ; Humans ; Lamivudine ; pharmacology ; therapeutic use ; Male ; Middle Aged ; Organophosphonates ; pharmacology ; therapeutic use ; Young Adult
9.In Silico Screening of Natural Products as Potential Inhibitors of SARS-CoV-2 Using Molecular Docking Simulation.
Rajib HOSSAIN ; Chandan SARKAR ; Shardar Mohammad Hafiz HASSAN ; Rasel Ahmed KHAN ; Mohammad ARMAN ; Pranta RAY ; Muhammad Torequl ISLAM ; Sevgi Durna DAŞTAN ; Javad SHARIFI-RAD ; Zainab M ALMARHOON ; Miquel MARTORELL ; William N SETZER ; Daniela CALINA
Chinese journal of integrative medicine 2022;28(3):249-256
OBJECTIVE:
To explore potential natural products against severe acute respiratory syndrome coronavirus (SARS-CoV-2) via the study of structural and non-structural proteins of human coronaviruses.
METHODS:
In this study, we performed an in-silico survey of 25 potential natural compounds acting against SARS-CoV-2. Molecular docking studies were carried out using compounds against 3-chymotrypsin-like protease (3CLPRO), papain-like protease (PLPRO), RNA-dependent RNA polymerase (RdRp), non-structural protein (nsp), human angiotensin converting enzyme 2 receptor (hACE2R), spike glycoprotein (S protein), abelson murine leukemia viral oncogene homolog 1 (ABL1), calcineurin-nuclear factor of activated T-cells (NFAT) and transmembrane protease serine 2.
RESULTS:
Among the screened compounds, amentoflavone showed the best binding affinity with the 3CLPRO, RdRp, nsp13, nsp15, hACE2R. ABL1 and calcineurin-NFAT; berbamine with hACE2R and ABL1; cepharanthine with nsp10, nsp14, nsp16, S protein and ABL1; glucogallin with nsp15; and papyriflavonol A with PLPRO protein. Other good interacting compounds were juglanin, betulinic acid, betulonic acid, broussooflavan A, tomentin A, B and E, 7-methoxycryptopleurine, aloe emodin, quercetin, tanshinone I, tylophorine and furruginol, which also showed excellent binding affinity towards a number of target proteins. Most of these compounds showed better binding affinities towards the target proteins than the standard drugs used in this study.
CONCLUSION
Natural products or their derivatives may be one of the potential targets to fight against SARS-CoV-2.
Animals
;
Antiviral Agents/therapeutic use*
;
Biological Products/pharmacology*
;
COVID-19/drug therapy*
;
Humans
;
Mice
;
Molecular Docking Simulation
;
SARS-CoV-2
10.Study of inhibitory effects of Gankang suppository on hepatitis B virus and its impact on serologic biochemistry in ducklings.
Hui LI ; De-ying TIAN ; Dong XU ; Liang WU ; Ming NI ; Xiao-jun MA
Chinese Journal of Hepatology 2007;15(4):307-308
Animals
;
Antiviral Agents
;
pharmacology
;
therapeutic use
;
Drugs, Chinese Herbal
;
pharmacology
;
therapeutic use
;
Ducks
;
Glycyrrhizic Acid
;
pharmacology
;
therapeutic use
;
Hepadnaviridae Infections
;
drug therapy
;
Hepatitis B Virus, Duck
;
drug effects
;
Hepatitis, Viral, Animal
;
drug therapy
;
Phytotherapy